Five days of oral topotecan (hycamtin®), a phase I and pharmacological study in adult patients with solid tumours
- 30 June 1998
- journal article
- clinical trial
- Published by Elsevier BV in European Journal of Cancer
- Vol. 34 (7), 1030-1035
- https://doi.org/10.1016/s0959-8049(97)10173-3
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitorBritish Journal of Cancer, 1996
- Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumorsInvestigational New Drugs, 1995
- Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeksCancer Chemotherapy and Pharmacology, 1995
- A phase II study of topotecan administered intravenously as 5 daily infusions every 21 days to women with refractory epithelial ovarian carcinomaEuropean Journal of Cancer, 1993
- Phase I Clinical and Pharmacology Study of Topotecan Given Daily for 5 Consecutive Days to Patients With Advanced Solid Tumors, With Attempt at Dose Intensification Using Recombinant Granulocyte Colony-Stimulating FactorJNCI Journal of the National Cancer Institute, 1993
- Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitorAnnals of Oncology, 1993
- Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activityJournal of Medicinal Chemistry, 1991
- Regulation of the function of eukaryotic DNA topoisomerase I: topological conditions for inactivity.Proceedings of the National Academy of Sciences of the United States of America, 1989
- Eukaryotic DNA topoisomerase I reaction is topology dependentNucleic Acids Research, 1988
- Evidence for an intermediate with a single-strand break in the reaction catalyzed by the DNA untwisting enzyme.Proceedings of the National Academy of Sciences of the United States of America, 1976